Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Generic: Donanemab
Donanemab is an investigational monoclonal antibody designed to target a modified form of beta-amyloid called N3pG. It is being developed for the treatment of early symptomatic Alzheimer's disease. Donanemab works by binding to and clearing these amyloid plaques, which are believed to contribute to the neurodegeneration seen in Alzheimer's disease. It is classified as a biologic therapeutic.
Donanemab is an investigational drug for the treatment of early symptomatic Alzheimer's disease.
Outcome:
Increased risk of bleeding
Mechanism:
Potential interference with coagulation cascade
Outcome:
Increased risk of gastrointestinal bleeding
Mechanism:
Additive effects on platelet function
Outcome:
Reduced absorption of donanemab
Mechanism:
Changes in stomach pH
Most likely new formulation: Subcutaneous injection (2025, 70% confidence)
Based on current clinical trial data, there is a high likelihood of FDA approval for donanemab in the next 2-3 years.
Monoclonal Antibody, Anti-Amyloid
IgG1 monoclonal antibody